DGN462

Item no.	HY-101150-5mg
Manufacturer	MedChem Express
CASRN	1394079-41-4
Amount	5mg
Quantity options	10mg 5mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Molecules
Specific against	other
Formula	C53H59N5O9S
Citations	[1]Hicks SW, et al. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Haematologica. 2019 Aug;104(8):1633-1639.
Smiles	O=C1N2[C@](CC3=C2C=CC=C3)([H])CNC4=CC(OCC5=CC(N(CC(C)(S)C)CCOCCOCCOC)=CC(COC6=C(OC)C=C7C(N8[C@](CC9=C8C=CC=C9)([H])C=NC7=C6)=O)=C5)=C(OC)C=C14
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Available
Product Description	DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML). DGN462 can be used as a cytotoxic component of antibody-drug conjugates (ADCs)[1].
Shipping	Room temperature
Manufacturers Applications	Cancer-programmed cell death
MolecularWeight	942.13
Clinical Information	No Development Reported
Manufacturers Research Area	Cancer
Solubility	10 mM in DMSO
Target	ADC Cytotoxin; DNA Alkylator/Crosslinker
Manufacturers Target	ADC Cytotoxin; DNA Alkylator/Crosslinker
Manufacturers Pathway	Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage
Manufacturers Product type	ADC Related

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 5mg

available

Request delivery time